Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00497224
Status:
COMPLETED
Last Update Posted:
2019-05-30
First Post:
2007-07-04
Brief Title:
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Organization Data
Organization:
University Health Network Toronto
Class:
OTHER
Study ID:
OSI-Tar-725
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University Health Network Toronto
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| OSI Pharmaceuticals | INDUSTRY |